Value proposition

Disrupting the Field of Biomarkers

BioMAdvanced Diagnostics is a MedTech start-up based in Nantes, spinoff from the CR2TI (Centre de Recherche Translationnelle en Transplantation et Immunologie, UMR 1064, INSERM – Nantes University) and from the University Hospital (CHU) of Nantes.

BioMAdvanced Diagnostics brings a real disruption in the field of Biomarkers based on 20 years of translational research. Its main goal is to enable a really personalized medicine which will greatly improve outcomes for the patient by providing unprecedented tools to clinicians.

More specifically, great attention is being placed towards diminishing risks for patients through minimal invasive solutions which will enable very substantial cost reductions for the Health Systems.

The first applications will concern the improvement of kidney or lungs transplanted patients’ follow up. The identification of biomarkers to evaluate, predict and diagnose the risk of transplant rejection will provide clinicians with ways of better anticipating and adapting their patients’ treatment. The goal being to reduce as much as possible numerous secondary effects. BioMAdvanced Diagnostics Tests will provide predictive scores and will be easily integrated into diagnostic and standard treatment protocols, easy to use by medical practitioners.

BioMAdvanced Diagnostics is incubated by Atlanpole and supported by SATT Ouest Valorisation.

In September 2023, the company announced a 2nd round of seed investment, raising an additional 1.4 million euros.

As of February 2024, BiomAdvanced Diagnostics is ISO 13485 certified by BSI under certificate number MD 775018.